<DOC>
	<DOCNO>NCT02881567</DOCNO>
	<brief_summary>The primary objective study evaluate effect treatment daclizumab proportion participant relapse-free 6 month Relapsing-Remitting Multiple Sclerosis ( RRMS ) participant , switch treatment natalizumab daclizumab due safety concern . The secondary objective study study population evaluate effect daclizumab follow : 1 ) Multiple Sclerosis ( MS ) relapse activity include annualized relapse rate ( ARR ) proportion participant experience relapse require hospitalization and/or steroid treatment ; 2 ) MS-related outcome measure use magnetic resonance imaging ( MRI ) ; 3 ) Safety tolerability participant previously treat natalizumab .</brief_summary>
	<brief_title>Efficacy Safety Daclizumab Participants With RRMS Switching From Natalizumab</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Key Inclusion Criteria Must document diagnosis RRMS ( McDonald 2010 Criteria ) screen [ Polman 2011 ] . Must treat natalizumab least 12 month prior screen miss 2 consecutive schedule dos . Must naïve daclizumab form daclizumab Zenapax® prior enrollment . Must confirm Expanded Disability Status Scale ( EDSS ) score 0 5.5 , inclusive , screen . Female participant childbearing potential must practice effective contraception Day 1 willing able continue contraception duration study . Key Exclusion Criteria Current participation another investigational study . Diagnosis primary progressive , secondary progressive , progressive relapsing MS ( define Lublin Reingold ) [ Lublin 2014 ] . Females breastfeeding , pregnant , plan become pregnant ; woman positive pregnancy test result screen . History drug alcohol abuse ( define Investigator ) within 1 year prior screen . History severe opportunistic infection ( include progressive multifocal leukoencephalopathy ( PML ) ) clinically significant , cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic ( MS ) , dermatologic , psychiatric , renal , major disease , determine Investigator . Discontinued natalizumab due suspicion PML . Known active malignancy ( participant cutaneous basal cell carcinoma completely excise prior study entry remain eligible ) . The participant use another MS therapy concomitantly . Known history human immunodeficiency virus ( HIV ) . Positive test result Hepatitis C virus ( test hepatitis C virus antibody [ HCV Ab ] ) hepatitis B virus ( test hepatitis B surface antigen [ HBsAg ] and/or hepatitis B core antibody [ HBcAb ] ) . The participant treat immunosuppressive immunomodulating treatment include mitoxantrone , azathioprine , methotrexate , cyclophosphamide , mycophenolate mofetil . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Daclizumab</keyword>
	<keyword>Tysabri-Switch</keyword>
</DOC>